Lopinavir/ritonavir - Abbvie

Drug Profile

Lopinavir/ritonavir - Abbvie

Alternative Names: ABT-378/r; ABT-378/ritonavir; Aluvia; Kaletra

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; University of Alberta
  • Class Amides; Antiretrovirals; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Jun 2017 Preregistration for HIV infections (In neonates, In infants, In children, In adolescents, In adults) in European Union (PO)
  • 23 Jun 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of lopinavir/ritonavir for HIV infections (In neonates, In infants, In children, In adolescents, In adults) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top